SNS-032 - Small Molecule (ID:10132-101)

HMS LINCS ID: 10132-101
Name: SNS-032
Alternative Names: BMS-387032
LINCS ID: LSM-1132
PubChem CID: 3025986
ChEBI ID:
ChEMBL ID:
Molecular Mass: 380.13
InChi: InChI=1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)
InChi Key: OUSFTKFNBAZUKL-UHFFFAOYSA-N
SMILES: CC(C)(C)C1=CN=C(O1)CSC2=CN=C(S2)NC(=O)C3CCNCC3
Relevant Citations:
Comments:
Date Publicly Available:
Most Recent Update: 2016-07-12

Target Affinity:

(see Study 20000)
Target Affinity Spectrum Value HUGO Gene Name
1
(Kd <100 nM)
CCNE1, CDK11A, CDK11B, CDK13, CDK16, CDK17, CDK18, CDK2, CDK3, CDK4, CDK7, CDK9, CDKL2, CDKL5, CDKN3, GSK3A, GSK3B
2
(equivalent to 100 nM ≤ Kd < 1µM)
CASK, CCNB1, CCNB2, CCNB3, CCND1, CCND2, CCND3, CDK1, CDK14, CDK15, CDK19, CDK5, CLK1, CLK4, CSNK1E, DYRK1A, DYRK1B, ICK, MAPK15, MAPK6, MAPK7, MYLK2, PHKG2, PRKD3, STK17A, STK36, TAOK3, TPTEP2-CSNK1E
3
(equivalent to 1µM ≤ Kd < 10 µM)
AURKA, AURKC, BRAF, BRSK2, CDC7, CDK8, CDKL3, CIT, CLK2, COQ8B, CSNK1A1, CSNK1D, DCLK1, DCLK2, DCLK3, DYRK2, FLT1, FLT3, GAK, GRK5, HIPK1, HIPK2, HIPK3, IRAK3, MAK, MAP3K7, MAP4K2, MAPK10, MAPK4, MAST1, MELK, MKNK1, MKNK2, MST1R, MYLK3, MYLK4, NUAK2, PAK3, PHKG1, PKD1, PKD2, PRKAA1, PRKD1, PRKD2, RIOK2, ROCK1, ROCK2, RPS6KA5, SGK2, TAOK1, TAOK2, TBK1, TGFBR2, ULK1
10
(confirmed non-binding)
(Click to show)

Datasets:

HMS Dataset ID Dataset Title HMS Dataset Type
20000
Target Affinity Spectrum (TAS) vectors for compounds in the HMS LINCS small molecule library.
Analysis
20237
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1.
 Microscopy/Imaging
20238
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2.
 Microscopy/Imaging
20239
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3.
 Microscopy/Imaging
20240
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1.
 Microscopy/Imaging
20241
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2.
 Microscopy/Imaging
20242
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3.
 Microscopy/Imaging
20243
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 7 of 15: Mean cell count and mean growth rate across all replicates.
 Microscopy/Imaging
20245
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1.
 Microscopy/Imaging
20246
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2.
 Microscopy/Imaging
20247
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3.
 Microscopy/Imaging
20248
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1.
 Microscopy/Imaging
20249
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2.
 Microscopy/Imaging
20250
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3.
 Microscopy/Imaging
20251
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 14 of 15: Mean cell count and mean normalized growth rate inhibition values across all replicates.
 Microscopy/Imaging
20252
LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 15 of 15: Calculated dose-response metrics.
 Analysis

Batch Information:

HMS LINCS Batch ID Provider Provider Batch ID
10132-101-1 Haoyuan chemexpress HY-126_TM-20081211
10132-101-3 MedChem Express 00615